President Trump announced on Monday that his administration has signed agreements with nine additional pharmaceutical companies to provide discounted medications to state Medicaid programs. During the announcement in the Oval Office, Trump stated that these agreements are expected to save Americans over $600 billion in a short period. The initiative is part of his "most-favored-nation" drug pricing policy, which aims to bring U.S. drug prices in line with those in other developed countries. This policy involves offering discounted medications directly to consumers through TrumpRx, a website launched in February by the Trump administration that provides discounts on brand-name medications. According to the White House, 17 pharmaceutical companies have already agreed to lower their drug prices as part of the "most-favored-nation" deal over the past year. Trump noted that with the latest announcement, 26 companies now represent 90% of the domestic pharmaceutical market, and the remaining 10% are expected to join soon. "They have no choice," he said, referring to the pressure on the remaining pharmaceutical firms to participate in the initiative. The nine newly added companies are midsize pharmaceutical firms, as outlined in a White House fact sheet. These include Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB. The White House stated that these companies will provide access to their drugs for every state Medicaid program across the United States, resulting in billions of dollars in savings for Americans. In addition to offering discounted medications, the companies have also committed to investing $19.6 billion in manufacturing, according to the Trump administration. This investment is intended to support domestic production and potentially contribute to long-term cost savings and job creation in the pharmaceutical sector.